statistiche ricercatore

Nome	#
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides.	99
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification	83
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines	82
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines	80
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer	76
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors)	75
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells	69
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer	63
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling	48
null	31
Totale	706

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2018/2019	19	0	0	0	0	0	0	0	0	0	0	19	0
2019/2020	123	18	19	4	2	8	14	24	2	13	5	5	9
2020/2021	46	1	4	2	1	7	0	3	0	12	4	12	0
2021/2022	46	2	0	0	7	1	2	5	5	3	5	6	10
2022/2023	221	19	24	18	22	20	25	1	13	71	0	5	3
2023/2024	68	2	9	3	3	7	18	5	16	4	1	0	0
Totale													706